With over 1.21 million BioLineRx Ltd. (BLRX) shares trading Tuesday and a closing price of $0.74 on the day, the dollar volume was approximately $0.9 million. The shares have shown a negative half year performance of -27.77% and its price on 03/21/23 gained nearly 16.94%. Currently, there are 49.38M common shares owned by the public and among those 44.42M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for BLRX have a consensus price objective of $9.67. The analysts have set the share’s price value over the next 12 months at a high of $19.00 and a low of $4.00. The average price target is 92.35% above its recent price level and an upside to the estimated low will see the stock gain 81.5% over that period. But an upside of 96.11% will see the stock hit the forecast high price target while median target price for the stock is $6.00.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The top 3 mutual fund holders in BioLineRx Ltd. are FCP Medical – BioHealth, APO Medical Opportunities, and RIM Global – Bioscience. FCP Medical – BioHealth owns 0.7 million shares of the company’s stock, all valued at over $0.42 million. APO Medical Opportunities bought 0.22 million shares to see its total holdings expand to 0.41 million shares valued at over $0.24 million and representing 0.66% of the shares outstanding. RIM Global – Bioscience now owns shares totaling to 0.18% of the shares outstanding.
Shares of BioLineRx Ltd. (NASDAQ: BLRX) opened at $0.6024, down -$0.03 from a prior closing price of $0.63. However, the script later moved the day high at 0.7500, up 16.94%. The company’s stock has a 5-day price change of 22.78% and 14.47% over the past three months. BLRX shares are trading 24.86% year to date (YTD), with the 12-month market performance down to -51.85% lower. It has a 12-month low price of $0.55 and touched a high of $1.98 over the same period. BLRX has an average intraday trading volume of 243.20K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 24.44%, 17.49%, and -25.88% respectively.
Institutional ownership of BioLineRx Ltd. (NASDAQ: BLRX) shares accounts for 19.40% of the company’s 49.38M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $42.61M and a beta (3y monthly) value of 1.81. The earnings-per-share (ttm) stands at -$0.49. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.62% over the week and 6.80% over the month.
Analysts forecast that BioLineRx Ltd. (BLRX) will achieve an EPS of -$0.15 for the current quarter, -$0.14 for the next quarter and -$0.38 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.16 while analysts give the company a high EPS estimate of -$0.14. Comparatively, EPS for the current quarter was -$0.15 a year ago. Earnings per share for the fiscal year are expected to increase by 65.60%, and -40.70% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate BioLineRx Ltd. (BLRX) as a “Strong Buy” at a consensus score of 1.50. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the BLRX, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on May 18, 2017, with the firm’s price target at $1-$3. Rodman & Renshaw coverage for the BioLineRx Ltd. (BLRX) stock in a research note released on February 13, 2017 offered a Buy rating with a price target of $3. Maxim Group was of a view on August 12, 2016 that the stock is Hold, while Maxim Group gave the stock Buy rating on August 17, 2015, issuing a price target of $8- $4. ROTH Capital on their part issued Buy rating on July 27, 2015.
